Ajmera Transplant Program, University Health Network, Toronto, ON, Canada; Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada; Institute of Medical Science, University of Toronto, Toronto, ON, Canada; Division of Gastroenterology & Hepatology, Department of Medicine, University of Toronto, Toronto, ON, Canada.
Ajmera Transplant Program, University Health Network, Toronto, ON, Canada; Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada; Institute of Medical Science, University of Toronto, Toronto, ON, Canada.
J Hepatol. 2023 Jun;78(6):1216-1233. doi: 10.1016/j.jhep.2023.01.006.
Liver transplantation (LT) is a life-saving treatment for individuals with end-stage liver disease. The management of LT recipients is complex, predominantly because of the need to consider demographic, clinical, laboratory, pathology, imaging, and omics data in the development of an appropriate treatment plan. Current methods to collate clinical information are susceptible to some degree of subjectivity; thus, clinical decision-making in LT could benefit from the data-driven approach offered by artificial intelligence (AI). Machine learning and deep learning could be applied in both the pre- and post-LT settings. Some examples of AI applications pre-transplant include optimising transplant candidacy decision-making and donor-recipient matching to reduce waitlist mortality and improve post-transplant outcomes. In the post-LT setting, AI could help guide the management of LT recipients, particularly by predicting patient and graft survival, along with identifying risk factors for disease recurrence and other associated complications. Although AI shows promise in medicine, there are limitations to its clinical deployment which include dataset imbalances for model training, data privacy issues, and a lack of available research practices to benchmark model performance in the real world. Overall, AI tools have the potential to enhance personalised clinical decision-making, especially in the context of liver transplant medicine.
肝移植(LT)是治疗终末期肝病患者的救命疗法。LT 受者的管理非常复杂,主要是因为需要在制定合适的治疗计划时考虑人口统计学、临床、实验室、病理学、影像学和组学数据。目前整理临床信息的方法存在一定程度的主观性;因此,LT 中的临床决策可以从人工智能 (AI) 提供的数据驱动方法中受益。机器学习和深度学习可应用于 LT 前后的各个环节。一些 AI 应用的例子包括优化移植候选决策和供体-受体匹配,以降低等待名单死亡率并改善移植后的结果。在 LT 后,AI 可以帮助指导 LT 受者的管理,特别是通过预测患者和移植物的存活率,以及识别疾病复发和其他相关并发症的风险因素。尽管 AI 在医学领域显示出巨大的潜力,但它在临床部署方面仍存在局限性,包括模型训练的数据不平衡、数据隐私问题,以及缺乏可用的研究实践来衡量模型在现实世界中的性能。总的来说,AI 工具有可能增强个性化临床决策,特别是在肝移植医学领域。